title: Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
abstract: The pricing and reimbursement policies for pharmaceuticals are relevant to balance timely and equitable access for all patients, financial sustainability, and reward for valuable innovation. The proliferation of high-cost specialty medicines is particularly true in rare diseases (RDs) where the pricing mechanism is characterised by a lack of transparency. This work provides an overall picture of current strategies for the definition of the reimbursed prices of orphan drugs (ODs) and highlights some potential improvements. Current strategies and suggestions are presented along 4 dimensions: (1) comprehensive value assessment, (2) early dialogs among relevant stakeholders, (3) innovative reimbursement approaches, and (4) societal participation in producing ODs. Comprehensive value assessment could be achieved by clarifying the approach of distributive justice to adopt, ensuring a representative participation of stakeholders, and with a broad consideration of value-bearing factors. With respect to early dialogs, cross-border cooperation can be determinant to companies and agencies. The cost-benefit ratio of early dialogs needs to be demonstrated and the "regulatory capture" effect should be monitored. Innovative reimbursement approaches were developed to balance the need for evidence-based decisions with the timely access to innovative drugs. The societal participation in producing ODs needs to be recognised in a collaborating framework where adaptive agreements can be developed with mutual satisfaction. Such agreements could also impact on coverage and reimbursement decisions as additional elements for the determination of a comprehensive societal value of ODs. Further research is needed to investigate the highlighted open challenges so that RDs will not remain, in practical terms, orphan diseases.
authors.affiliation: Institute for Research on Population and Social Policies, URT Brindisi, National Research Council of Italy, Brindisi, Italy.
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Mincarone
authors.forename: Carlo Giacomo
authors.initials: CG
authors.lastname: Leo
authors.forename: Saverio
authors.initials: S
authors.lastname: Sabina
authors.forename: Antonio
authors.initials: A
authors.lastname: Sarriá-Santamera
authors.forename: Domenica
authors.initials: D
authors.lastname: Taruscio
authors.forename: Pedro Guillermo
authors.initials: PG
authors.lastname: Serrano-Aguilar
authors.forename: Panos
authors.initials: P
authors.lastname: Kanavos
mesh_terms: D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007400:Interprofessional Relations; D009965:Orphan Drug Production / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000191:economics*
keywords: Access to healthcare; Early dialog; Orphan drugs; Pricing; Technology assessment, biomedical [MeSH]